Does Ceftaroline Cover MRSA?
Yes, ceftaroline has excellent activity against MRSA and is FDA-approved for treating acute bacterial skin and skin structure infections (ABSSSI) caused by MRSA, including cases with concurrent bacteremia. 1
Mechanism and Spectrum of Activity
Ceftaroline is a novel cephalosporin that achieves its anti-MRSA activity through high-affinity binding to PBP2a, the altered penicillin-binding protein that confers methicillin resistance in S. aureus 1. This unique mechanism allows it to overcome the resistance mechanism that renders traditional beta-lactams ineffective against MRSA.
The FDA label explicitly states that ceftaroline is active against "Staphylococcus aureus (including methicillin-susceptible and -resistant isolates)" for skin infections 1. However, for community-acquired bacterial pneumonia (CABP), the FDA approval only covers methicillin-susceptible S. aureus, not MRSA 1.
In Vitro Susceptibility Data
Recent surveillance data demonstrates robust activity:
- 99.4% of MRSA isolates were susceptible to ceftaroline in a 2026 Indian tertiary care study, with MIC values predominantly ranging from 0.1-0.4 µg/mL 2
- 84.8% susceptibility with 14.4% intermediate susceptibility in another 2026 study of 250 MRSA isolates 3
- 97.5% of MRSA strains inhibited at ≤1 mcg/mL in US surgical site infections 4
The susceptibility remains consistent across different patient demographics, hospital departments, and specimen types 3.
Clinical Efficacy in MRSA Infections
FDA-Approved Indication (ABSSSI)
The 2011 IDSA MRSA guidelines note that ceftaroline was under FDA review at the time of publication and has since been approved for complicated skin and soft tissue infections 5. The drug has now been FDA-approved and extensively studied.
Off-Label Use in MRSA Bacteremia
While not FDA-approved for MRSA bacteremia, emerging evidence supports its use:
- Ceftaroline was non-inferior to daptomycin for MRSA bloodstream infections in a multicenter cohort (composite failure: 32.5% vs 39%, weighted risk difference 7.0%, 95% CI -5.0% to 19.0%) 6
- Mean clinical cure of 74% across 379 patients with severe MRSA infections in a systematic review 7
- Combination therapy with vancomycin or daptomycin showed efficacy in high-risk MRSA bacteremia cases 8
Important Clinical Caveats
Critical limitation: The 2011 IDSA guidelines do not include ceftaroline in their formal treatment recommendations for MRSA infections because it was not yet FDA-approved at the time of guideline publication 5. The guidelines list vancomycin, linezolid, daptomycin, and telavancin as approved options for complicated SSTI, with clindamycin for outpatients 5.
For MRSA bacteremia specifically: Vancomycin remains the guideline-recommended standard of care 9. While ceftaroline shows promise in observational studies, a 2024 study found that early ceftaroline-based combination therapy did not improve outcomes compared to monotherapy and actually prolonged time to microbiological cure (mean difference 1.50 days) 10.
Safety Profile
Ceftaroline is generally well-tolerated:
- Rash occurs more frequently than with daptomycin (10.8% vs 1.1%) 6
- No creatine phosphokinase elevation compared to 5.3% with daptomycin 6
- Hematological monitoring required with prolonged courses 7
- Dosage adjustment needed for renal impairment 1
Practical Recommendations
For ABSSSI with confirmed or suspected MRSA: Ceftaroline 600 mg IV every 12 hours is an FDA-approved option and represents a valid alternative to vancomycin, linezolid, or daptomycin 1.
For MRSA bacteremia or endocarditis: Use ceftaroline only when standard therapies (vancomycin, daptomycin) have failed, are contraindicated, or in combination therapy for high-risk cases. This remains off-label use 8.
Do not use ceftaroline for MRSA pneumonia as the FDA approval for CABP only covers methicillin-susceptible S. aureus 1.